Marko Lucijanić

1.8k total citations
119 papers, 857 citations indexed

About

Marko Lucijanić is a scholar working on Genetics, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Marko Lucijanić has authored 119 papers receiving a total of 857 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Genetics, 27 papers in Infectious Diseases and 25 papers in Molecular Biology. Recurrent topics in Marko Lucijanić's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers), COVID-19 Clinical Research Studies (25 papers) and Kruppel-like factors research (21 papers). Marko Lucijanić is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers), COVID-19 Clinical Research Studies (25 papers) and Kruppel-like factors research (21 papers). Marko Lucijanić collaborates with scholars based in Croatia, Serbia and United States. Marko Lucijanić's co-authors include Rajko Kušec, Ivan Krečak, Marko Skelin, Tomo Lucijanić, Vlatko Pejša, Srečko Marušić, Tajana Štoos‐Veić, Ivica Lukšić, Maja Ortner Hadžiabdić and Mladen Petrovečki and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Scientific Reports.

In The Last Decade

Marko Lucijanić

107 papers receiving 849 citations

Peers

Marko Lucijanić
Leonard Naymagon United States
Vilmarie Rodriguez United States
Michelle Sholzberg Canada
G. Pugnet France
Marianne Laouri United States
Y. Benhamou France
Nada Alachkar United States
Sergey Postovsky Israel
Florian Moik Austria
Anupam Kotwal United States
Leonard Naymagon United States
Marko Lucijanić
Citations per year, relative to Marko Lucijanić Marko Lucijanić (= 1×) peers Leonard Naymagon

Countries citing papers authored by Marko Lucijanić

Since Specialization
Citations

This map shows the geographic impact of Marko Lucijanić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marko Lucijanić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marko Lucijanić more than expected).

Fields of papers citing papers by Marko Lucijanić

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marko Lucijanić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marko Lucijanić. The network helps show where Marko Lucijanić may publish in the future.

Co-authorship network of co-authors of Marko Lucijanić

This figure shows the co-authorship network connecting the top 25 collaborators of Marko Lucijanić. A scholar is included among the top collaborators of Marko Lucijanić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marko Lucijanić. Marko Lucijanić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lucijanić, Marko, et al.. (2025). Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations. Cancers. 17(9). 1390–1390.
2.
3.
4.
Hadžiabdić, Maja Ortner, et al.. (2024). Corticosteroid Dosing Level, Incidence and Profile of Bacterial Blood Stream Infections in Hospitalized COVID-19 Patients. Viruses. 16(1). 86–86. 1 indexed citations
5.
Krečak, Ivan, et al.. (2024). Systemic Inflammatory Index in Polycythemia Vera and Its Prognostic Implications. Journal of Clinical Medicine. 13(15). 4459–4459. 3 indexed citations
6.
7.
Krečak, Ivan, Danijela Leković, Andrija Bogdanović, & Marko Lucijanić. (2024). High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera. Leukemia & lymphoma. 65(11). 1724–1728. 2 indexed citations
8.
Krečak, Ivan, et al.. (2024). Diabetes mellitus, metformin, and the risk of MPN. Blood Advances. 8(22). 5929–5931. 1 indexed citations
9.
Lucijanić, Marko, et al.. (2024). Cyberchondria, Health Literacy, and Perception of Risk in Croatian Patients with Risk of Sexually Transmitted Infections and HIV—A Cross-Sectional Study. SHILAP Revista de lepidopterología. 5(3). 525–538. 2 indexed citations
10.
11.
Lucijanić, Marko, et al.. (2023). Predictors of prolonged hospitalization of COVID-19 patients. European Geriatric Medicine. 14(3). 511–516. 5 indexed citations
12.
Lucijanić, Marko, et al.. (2023). Incidence, Risk Factors and Mortality Associated with Major Bleeding Events in Hospitalized COVID-19 Patients. Life. 13(8). 1699–1699. 3 indexed citations
13.
Lucijanić, Marko, et al.. (2023). Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events. The American Journal of Emergency Medicine. 70. 41–45. 5 indexed citations
14.
Krečak, Ivan, Srđan Verstovšek, & Marko Lucijanić. (2023). Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives. Annals of Hematology. 103(5). 1513–1523. 5 indexed citations
15.
Krečak, Ivan & Marko Lucijanić. (2023). Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction. JACC CardioOncology. 5(6). 842–842. 1 indexed citations
16.
Lucijanić, Marko, et al.. (2023). Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate. Expert Opinion on Drug Safety. 22(12). 1265–1270.
17.
Krečak, Ivan, Marko Lucijanić, & Srđan Verstovšek. (2022). Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia. Current Hematologic Malignancy Reports. 17(5). 155–169. 14 indexed citations
18.
Krečak, Ivan, et al.. (2022). Chronic Kidney Disease has a Higher Prevalence in Polycythemia Vera than in Secondary Polycythemia, a Matched Case–Control Analysis. Indian Journal of Hematology and Blood Transfusion. 39(4). 708–709. 1 indexed citations
19.
Lucijanić, Marko, et al.. (2020). C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis. Leukemia & lymphoma. 61(12). 2969–2974. 6 indexed citations
20.
Lucijanić, Marko, et al.. (2017). NEUROSYPHILIS IN ANGLOAMERICAN COMPOSERS AND JAZZ MUSICIANS. SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonard Naymagon Breakdown of academic impact, for papers by Vilmarie Rodriguez Breakdown of academic impact, for papers by Michelle Sholzberg Breakdown of academic impact, for papers by G. Pugnet Breakdown of academic impact, for papers by Marianne Laouri Breakdown of academic impact, for papers by Y. Benhamou Breakdown of academic impact, for papers by Nada Alachkar Breakdown of academic impact, for papers by Sergey Postovsky Breakdown of academic impact, for papers by Florian Moik Breakdown of academic impact, for papers by Anupam Kotwal
Rankless by CCL
2026